Chandan Healthcare has confirmed that no encumbrance has been created or invoked on the shares held by its promoters during the financial year ended March 31, 2026. The company submitted a yearly declaration to the National Stock Exchange of India Ltd. on April 06, 2026, in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This disclosure provides assurance to shareholders regarding the status of promoter holdings and the absence of undisclosed liabilities or pledges against these shares.

The declaration, signed by Promoter Amar Singh, states that there are no subsisting encumbrances on the shares held by promoters as on March 31, 2026, other than those already disclosed to the stock exchange. The promoters further confirmed that all disclosures required under Regulation 31(1), 31(2), and 31(3) of the SEBI (SAST) Regulations, 2011 have been duly complied with. The filing was submitted by Rajeev Kumar Nain, Company Secretary & Compliance Officer of Chandan Healthcare Limited.

The declaration was submitted on behalf of the promoters and Persons Acting in Concert (PACs). The document identifies the key promoters associated with the company, confirming their adherence to regulatory norms concerning shareholding disclosures.

Chandan Healthcare Limited has filed the Monitoring Agency Report for the quarter ended March 31, 2026, with the National Stock Exchange of India Ltd., pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 162A and Schedule XI of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The report, prepared by Crisil Ratings Limited as the designated Monitoring Agency, pertains to the utilisation of proceeds from the company's preferential issue of fully convertible warrants. The report has been reviewed by the Audit Committee and approved by the Board of Directors of the company.

Issue Overview

The preferential issue was conducted on February 3, 2026, with a total issue size of Rs 1,04,13,00,000. The issue comprised fully convertible warrants, with the company having received 25% of the total issue proceeds at the time of allotment. The remaining 75%, amounting to Rs 78,09,75,000, is yet to be received and shall be payable by the warrant holders upon conversion of warrants into equity shares within 18 months from the date of allotment, i.e., by July 28, 2027, as per the notice to shareholders.

The key details of the issue are summarised below:

Utilisation of Issue Proceeds

During the quarter ended March 31, 2026, the company utilised a total of Rs 16,93,07,881 out of the received proceeds. The utilisation was spread across two objects — Business Expansion and General Corporate Purposes — while no amount was deployed towards Acquisitions during the reported quarter. The following table presents the object-wise progress in utilisation:

As noted in the report, during the quarter ended March 31, 2026, out of the utilised proceeds of Rs 16,93,07,881, an amount of Rs 12,17,53,881 was transferred to current accounts of the company for utilisation towards Object 1: Business Expansion for operational ease, and the transferred proceeds were fully utilised as at the end of the reported quarter. The General Corporate Purposes utilisation of Rs 4,75,54,000 pertained to payment of professional fees, as per the notice to shareholders.

Deployment of Unutilised Proceeds

The unutilised proceeds received by the company have been deployed in fixed deposits and maintained in the preferential issue account. The deployment details as at March 31, 2026 are as follows:

Monitoring Agency Observations

Crisil Ratings Limited confirmed that the utilisation during the quarter is as per the disclosures in the notice to shareholders, with no deviation from the objects of the issue. The Monitoring Agency reported no material deviations, no changes in the means of finance, no major deviations over earlier monitoring agency reports, and no unfavorable events affecting the viability of the objects. No revision in the cost of any object was observed. The report was prepared on the basis of management undertakings, a statutory auditors' certificate dated May 07, 2026 issued by M/s MSNT & Associates LLP, Chartered Accountants (Firm Registration Number: 018542C), notice to shareholders, and bank statements.

Compliance and Regulatory Context

The report was submitted to the National Stock Exchange of India Ltd. on May 12, 2026, by Rajeev Kumar Nain, Company Secretary and Compliance Officer of Chandan Healthcare Limited. The Monitoring Agency Report was issued by Crisil Ratings Limited on May 11, 2026, and signed by Shounak Chakravarty, Director, Ratings (LCG). The report is also available on the company's website. No delay in implementation of the objects was reported, and no government or statutory approvals were identified as pending for the objects of the issue.